Dissertation > Excellent graduate degree dissertation topics show

Association of Expression of ERCC1/RRM1 with Survival and Resistance to Platinum Inpatients with Ⅰ-ⅢA NSCLC

Author: ZuoXiaoYu
Tutor: YinLiu
School: Dalian Medical University
Course: Oncology
Keywords: ERCC1 (Excision repair cross-complementation gene 1 excision repair cross complementing gene 1 ) RRM1 (Ribonucleotide reductase subunit 1 ribonucleotide reductase MI) Non-small cell lung cancer (NSCLC) Survival (OS) Disease-free survival (DFS)
CLC: R734.2
Type: Master's thesis
Year: 2011
Downloads: 32
Quote: 0
Read: Download Dissertation

Abstract


Objective: To analyze the nucleotide excision repair system members ERCC1/RRM1 in Ⅰ - Ⅲ A non-small cell lung cancer (NSCLC) tissue levels to explore its survival in NSCLC patients with platinum-resistant and relevance, patients with NSCLC individualized treatment to provide a theoretical basis. Materials and Methods: 1. Randomly selected 280 cases in our hospital 2004-2007 NSCLC patients after surgery, and follow-up clinical data aggregated survival, screened 160 patients enrolled in the study. (2) using tissue micro array systems planting cut tissue samples were detected by immunohistochemistry in lung cancer ERCC1/RRM1 expression levels. 3 using X2 inspection, Kaplan Meier survival analysis method, the survival curve for log-rank test, and Cox proportional hazards regression model analysis of multiple survival factors, the application of Spearman correlation analysis to explore the correlation between the expression ERCC1/RRM1. Results: 1.ERCC1 RRM1 in NSCLC tissues with positive expression rates were 55% and 49%. 2 in NSCLC ERCC1 expression with age, gender, smoking index, histological type and lymph node metastasis was no significant correlation (P gt; 0.05), with the degree of tumor differentiation correlated with statistical significance (P = 0.04 ), showed lower the degree of tumor differentiation ERCC1-positive rate. NSCLC, RRM1 expression and age, gender, smoking index, histological type, degree of differentiation and lymph node metastasis was no significant correlation (P gt; 0.05). 3.160 cases of patients, ERCC1/RRM1 negative expression prolonged survival compared to positive, the difference was not statistically significant (P gt; 0.05). 4 follow-up of patients with stage Ⅰ B NSCLC survival, ERCC1 expression is longer than those with negative expression, but the difference was not statistically significant (P gt; 0.05), RRM1 positive longer than the lifetime of the negative, the difference was statistically significant (P = 0.03); follow-Ⅱ - Ⅲ A survival of NSCLC patients, ERCC1 expression was negative than positive group extension, the difference was statistically significant (P = 0.03), RRM1 negative group prolong survival compared to positive group, but the difference was not statistically significant ( P gt; 0.05). 5. Ⅰ B expression of ERCC1/RRM1 positive, no chemotherapy group survival compared with chemotherapy prolonged survival of the group, but the difference was not statistically significant (P gt; 0.05); Ⅰ B negative expression of ERCC1/RRM1 when without chemotherapy prolonged survival compared to chemotherapy group, the difference was not statistically significant (P gt; 0.05). 6 Observe Ⅱ - Ⅲ A period RRM1 expression levels are the same, GP regimen on survival, the results show: RRM1 expression was negative when, GP regimen group, the median survival compared to TP, NP and other platinum-containing chemotherapy patients prolonged survival (40 months: 36 months), the difference was not statistically significant (P = 0.21); RRM1 expression, the other with platinum-based chemotherapy group, the median survival time is longer than the GP regimen chemotherapy group, the difference was not statistically significance (P = 0.12). 7 Multivariate Cox regression analysis showed: lymph node metastasis, histological type, tumor differentiation NSCLC patients is an independent prognostic factor. Conclusion: 1.ERCC1 protein in NSCLC tissues with gender, age, smoking index, histological type and lymph node metastasis, and degree of differentiation; RRM1 protein in NSCLC tissues with gender, age, smoking index, histological type , differentiation and lymph node metastasis. 2. Ⅰ B adjuvant chemotherapy in patients more harm than good. 3.ERCC1 expression and Ⅱ - Ⅲ A NSCLC, platinum-containing chemotherapy efficacy related to expression, the chemotherapy group compared with no chemotherapy group poor efficacy. 4.RRMl expression when, GP program than TP, NP and other platinum-containing chemotherapy regimens suboptimal; negative expression when, GP program than TP, NP and other platinum-based chemotherapy is effective. 5.ERCC1 with RRM1 has obvious relevance.

Related Dissertations

  1. Preliminary Study on the Relationship between Non-small Cell Lung Epithelial Mesenchymal Transition and Metastasis and Its Influencing Factors,R734.2
  2. The Prospective Study and Prognosis Analysis of NSCLC Treated by "Invigorating Spleen, Vital Engery & Phlegm Elimination" of TCM and the Combination Therapy with TCM and Cisplatin.,R734.2
  3. Non-small cell lung VEGF and its receptors Flt-1 expression and clinical significance,R734.2
  4. Expression and Clinical Significance of CXCR4 and HPA in Non-small Cell Lung Cancer Cells,R734.2
  5. Clinical Study of Endostar Combined with Pemetrexed for Advanced Non-small Cell Lung Cancer,R734.2
  6. The Expression of Granulocyte Colony Stimulating Factor (G-CSF) in Non Small Cell Lung Cancer (NSCLC) and Its Clinicopathological Significance,R734.2
  7. Polyphenols and joint angiogenesis inhibitor anti - lung adenocarcinoma xenograft tumor angiogenesis, the molecular mechanism of,R734.2
  8. Expression and Significance of Survivin and CyclinD1 in Human Non-small Cell Lung Cancer,R734.2
  9. The Study of CD44s Expression of Lung Cancer Cells and Peripheral Blood Lymphocytes in NSCLC,R734.2
  10. CpG Island Methylator Phenotype Involving Tumor Suppressor Genes Located on Chromosome 3p in Non-Small Cell Lung Cancer,R734.2
  11. Detection and Quantitation of Circulation Tumor Cells in Patients with Non-small Cell Lung Cancer Using Immunomagnetic Enrichment and Multiparameter Flow Cytometry,R734.2
  12. Righting cancer combined NP regimen in advanced non-small cell lung cancer,R734.2
  13. Evidence Based Medical Research on Non-small Cell Lung Cancer,R734.2
  14. The Clinical Significance of the Expression of Livin in Non-small Cell Lung Cancer,R734.2
  15. Study on Chromosomal Imbalances Associated with Chemoresistance and Proteins Correlated with Chemotherapeutic Sensitivity in Advanced Non-small Cell Lung Cancer,R734.2
  16. The Clinical Study of 10-Hydroxycamplothecin(HCPT) as Radiosensitivity Agent Plus Radiotherapy(RT) on Treatment Local Advanced Non-small Cell Lung Cancer (LANSCLC),R734.2
  17. The Prospective Study and Prognosis Analysis of the Elderly Patients with Advanced Non-small-Cell Lung Cancer (NSCLC) Treated by "Benefiting Vital Energy and Eliminating Phlegm" of Traditional Chinese Medicine (TCM).,R734.2
  18. Study on Expression and Promoter Methylation of APAF-1 Gene in Non-Small Cell Lung Cancer and Effects of 5-Aza-2’-deoxycytidine on Proliferation of Human Lung Adenocarcinoma Cell Lines,R734.2
  19. Study of the Inhibitory Effect of Src Kinase Inhibitor M475271 on NSCLC and the Mechanism,R734.2
  20. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor and the Monoclonal Antibody in No-Small Cell Lung Cancer,R734.2

CLC: > Medicine, health > Oncology > Respiratory system tumors > Lung tumors
© 2012 www.DissertationTopic.Net  Mobile